Pablo Sarobe

List of Publications by Year
in descending order

110 papers	5,273 citations	87723 38 h-index	95083 68 g-index
113 all docs	113 docs citations	113 times ranked	7037 citing authors

#	Article	IF	Citations
1	A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. Journal of Hepatology, 2013, 59, 81-88.	1.8	816
2	Advances in immunotherapy for hepatocellular carcinoma. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 525-543.	8.2	609
3	PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity. Cell Reports, 2017, 20, 1818-1829.	2.9	220
4	CD4+/CD25+ Regulatory Cells Inhibit Activation of Tumor-Primed CD4+ T Cells with IFN-Î³-Dependent Antiangiogenic Activity, as well as Long-Lasting Tumor Immunity Elicited by Peptide Vaccination. Journal of Immunology, 2003, 171, 5931-5939.	0.4	186
5	Abnormal Priming of CD4+ T Cells by Dendritic Cells Expressing Hepatitis C Virus Core and E1 Proteins. Journal of Virology, 2002, 76, 5062-5070.	1.5	141
6	Hepatitis C Virus Structural Proteins Impair Dendritic Cell Maturation and Inhibit In Vivo Induction of Cellular Immune Responses. Journal of Virology, 2003, 77, 10862-10871.	1.5	127
7	Upregulation of Indoleamine 2,3-Dioxygenase in Hepatitis C Virus Infection. Journal of Virology, 2007, 81, 3662-3666.	1.5	116
8	Depletion of Dendritic Cells Delays Ovarian Cancer Progression by Boosting Antitumor Immunity. Cancer Research, 2008, 68, 7684-7691.	0.4	105
9	Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model. Cancer Immunology, Immunotherapy, 2019, 68, 379-393.	2.0	100
10	Expansion of Tumor-Infiltrating CD8+ T cells Expressing PD-1 Improves the Efficacy of Adoptive T-cell Therapy. Cancer Research, 2017, 77, 3672-3684.	0.4	99
11	A Peptide Inhibitor of FOXP3 Impairs Regulatory T Cell Activity and Improves Vaccine Efficacy in Mice. Journal of Immunology, 2010, 185, 5150-5159.	0.4	97
12	The Extra Domain A from Fibronectin Targets Antigens to TLR4-Expressing Cells and Induces Cytotoxic T Cell Responses In Vivo. Journal of Immunology, 2007, 178, 748-756.	0.4	89
13	A synthetic peptide from transforming growth factor-Â1 type III receptor prevents myocardial fibrosis in spontaneously hypertensive rats. Cardiovascular Research, 2008, 81, 601-609.	1.8	89
14	Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding positions.. Journal of Clinical Investigation, 1998, 102, 1239-1248.	3.9	88
15	Trial of complete weaning from immunosuppression for liver transplant recipients: Factors predictive of tolerance. Liver Transplantation, 2013, 19, 937-944.	1.3	87
16	Immunization with a tumor-associated CTL epitope plus a tumor-related or unrelated Th1 helper peptide elicits protective CTL immunity. European Journal of Immunology, 2001, 31, 1780-1789.	1.6	77
17	Is plasma cardiotrophin-1 a marker of hypertensive heart disease?. Journal of Hypertension, 2005, 23, 625-632.	0.3	72
18	Identification of peptide inhibitors of transforming growth factor beta 1 using a phage-displayed peptide library. Cytokine, 2007, 39, 106-115.	1.4	69

#	Article	IF	Citations
19	Hepatitis C virus induces the expression of CCL17 and CCL22 chemokines that attract regulatory T cells to the site of infection. Journal of Hepatology, 2011, 54, 422-431.	1.8	68
20	Therapeutic effect of a peptide inhibitor of TGF-Î² on pulmonary fibrosis. Cytokine, 2011, 53, 327-333.	1.4	66
21	Induction of Monocyte Chemoattractant Protein-1 and Interleukin-10 by TGFÎ²1 in Melanoma Enhances Tumor Infiltration and Immunosuppression. Cancer Research, 2011, 71, 812-821.	0.4	65
22	In Vitro and In Vivo Down-Regulation of Regulatory T Cell Activity with a Peptide Inhibitor of TGF-Î²1. Journal of Immunology, 2008, 181, 126-135.	0.4	63
23	Adjuvant Combination and Antigen Targeting as a Strategy to Induce Polyfunctional and High-Avidity T-Cell Responses against Poorly Immunogenic Tumors. Cancer Research, 2011, 71, 3214-3224.	0.4	63
24	Peptide inhibitors of transforming growth factorâ€Î²2 enhance the efficacy of antitumor immunotherapy. International Journal of Cancer, 2009, 125, 2614-2623.	2.3	62
25	Polarity of immunogens: implications for vaccine design. European Journal of Immunology, 1990, 20, 2363-2366.	1.6	57
26	Vaccination with an adenoviral vector encoding hepatitis C virus (HCV) NS3 protein protects against infection with HCV-recombinant vaccinia virus. Vaccine, 2002, 21, 202-210.	1.7	57
27	Radioembolization of hepatocellular carcinoma activates liver regeneration, induces inflammation and endothelial stress and activates coagulation. Liver International, 2015, 35, 1590-1596.	1.9	55
28	Therapeutic vaccination of woodchucks against chronic woodchuck hepatitis virus infection. Journal of Hepatology, 1997, 27, 726-737.	1.8	50
29	Specific and general HLA-DR binding motifs: comparison of algorithms. Human Immunology, 2000, 61, 266-278.	1.2	50
30	Simple strategy to induce antibodies of distinct specificity: Application to the mapping of gp120 and inhibition of HIV-1 infectivity. European Journal of Immunology, 1995, 25, 877-883.	1.6	48
31	Induction of cytotoxic T lymphocytes in mice against the principal neutralizing domain of HIV-1 by immunization with an engineered T-cytotoxic-T-helper synthetic peptide construct. Cellular Immunology, 1992, 141, 211-218.	1.4	45
32	Combined immunization with adjuvant molecules poly(I:C) and anti-CD40 plus a tumor antigen has potent prophylactic and therapeutic antitumor effects. Cancer Immunology, Immunotherapy, 2008, 57, 19-29.	2.0	44
33	Inhibition of FOXP3/NFAT Interaction Enhances T Cell Function after TCR Stimulation. Journal of Immunology, 2015, 195, 3180-3189.	0.4	44
34	Identification of an antigenic epitope for helper T lymphocytes from carcinoembryonic antigen. Clinical Cancer Research, 2002, 8, 3219-25.	3.2	44
35	IL-10 expression defines an immunosuppressive dendritic cell population induced by antitumor therapeutic vaccination. Oncotarget, 2017, 8, 2659-2671.	0.8	41
36	Insights on the amino acid side-chain interactions of a synthetic T-cell determinant. Biologicals, 1991, 19, 187-190.	0.5	40

#	Article	IF	Citations
37	Induction of antibodies against a peptide hapten does not require covalent linkage between the hapten and a class II presentable T helper peptide. European Journal of Immunology, 1991, 21, 1555-1558.	1.6	40
38	Production of interleukin-2 in response to synthetic peptides from hepatitis C virus E1 protein in patients with chronic hepatitis C: relationship with the response to interferon treatment. Journal of Hepatology, 1996, 25, 1-9.	1.8	40
39	Vaccination Against Hepatitis C Virus With Dendritic Cells Transduced With an Adenovirus Encoding NS3 Protein. Molecular Therapy, 2008, 16, 210-217.	3.7	39
40	ICOS Costimulation at the Tumor Site in Combination with CTLA-4 Blockade Therapy Elicits Strong Tumor Immunity. Molecular Therapy, 2019, 27, 1878-1891.	3.7	38
41	Enhancement of CD4 and CD8 immunity by anti-CD137 (4-1BB) monoclonal antibodies during hepatitis C vaccination with recombinant adenovirus. Vaccine, 2005, 23, 3493-3499.	1.7	36
42	Eradication of large tumors expressing human papillomavirus E7 protein by therapeutic vaccination with E7 fused to the extra domain a from fibronectin. International Journal of Cancer, 2012, 131, 641-651.	2.3	34
43	Oncostatin M Enhances the Antiviral Effects of Type I Interferon and Activates Immunostimulatory Functions in Liver Epithelial Cells. Journal of Virology, 2009, 83, 3298-3311.	1.5	33
44	T-helper cell response to woodchuck hepatitis virus antigens after therapeutic vaccination of chronically-infected animals treated with lamivudine. Journal of Hepatology, 2001, 35, 105-111.	1.8	30
45	Blockage of FOXP3 transcription factor dimerization and FOXP3/AML1 interaction inhibits T regulatory cell activity: sequence optimization of a peptide inhibitor. Oncotarget, 2017, 8, 71709-71724.	0.8	27
46	Improved dendritic cell-based immunization against hepatitis C virus using peptide inhibitors of interleukin 10. Hepatology, 2011, 53, 23-31.	3.6	25
47	Enhanced T cell responses against hepatitis C virus by ex vivo targeting of adenoviral particles to dendritic cells. Hepatology, 2011, 54, 28-37.	3.6	25
48	Immune monitoring of immunosuppression withdrawal of liver transplant recipients. Transplant Immunology, 2015, 33, 110-116.	0.6	25
49	Enhancing immunogenicity of a CTL epitope from carcinoembryonic antigen by selective amino acid replacements. Clinical Cancer Research, 2002, 8, 2336-44.	3.2	25
50	A recombinant adenovirus encoding hepatitis C virus core and E1 proteins protects mice against cytokine-induced liver damage. Hepatology, 2003, 37, 461-470.	3.6	23
51	Indoles and pyridazino[4,5-b]indoles as nonnucleoside analog inhibitors of HIV-1 reverse transcriptase. European Journal of Medicinal Chemistry, 1995, 30, 963-971.	2.6	21
52	Th1 but not Th0 cell help is efficient to induce cytotoxic T lymphocytes by immunization with short synthetic peptides. International Immunology, 1999, 11, 2025-2034.	1.8	21
53	Carcinoembryonic Antigen as a Target to Induce Anti-Tumor Immune Responses. Current Cancer Drug Targets, 2004, 4, 443-454.	0.8	21
54	Immunization against hepatitis C virus with a fusion protein containing the extra domain A from fibronectin and the hepatitis C virus NS3 protein. Journal of Hepatology, 2009, 51, 520-527.	1.8	21

#	Article	IF	Citations
55	Low molecular weight hyaluronan preconditioning of tumor-pulsed dendritic cells increases their migratory ability and induces immunity against murine colorectal carcinoma. Cancer Immunology, Immunotherapy, 2011, 60, 1383-1395.	2.0	21
56	Combination of a TLR4 ligand and anaphylatoxin C5a for the induction of antigen-specific cytotoxic T cell responses. Vaccine, 2012, 30, 2848-2858.	1.7	21
57	Tim-3 expression in tumour-associated macrophages: a new player in HCC progression. Gut, 2015, 64, 1502-1503.	6.1	20
58	Vaccine-induced but not tumor-derived Interleukin-10 dictates the efficacy of Interleukin-10 blockade in therapeutic vaccination. OncoImmunology, 2016, 5, e1075113.	2.1	20
59	Characterization of an immunologically conserved epitope from hepatitis C virus E2 glycoprotein recognized by HLA-A2 restricted cytotoxic T lymphocytes. Journal of Hepatology, 2001, 34, 321-329.	1.8	19
60	Dysregulation of interferon regulatory factors impairs the expression of immunostimulatory molecules in hepatitis C virus genotype 1-infected hepatocytes. Gut, 2014, 63, 665-673.	6.1	19
61	Characterization of T-cell responses against immunodominant epitopes from hepatitis C virus E2 and NS4a proteins. Journal of Viral Hepatitis, 2006, 13, 47-55.	1.0	18
62	Enhancement of peptide immunogenicity by insertion of a cathepsin B cleavage site between determinants recognized by B and T cells. Research in Immunology, 1993, 144, 257-262.	0.9	17
63	The DSS LOGDIS Optimizes Delivery Routes for FRILACâ€™s Frozen Products. Interfaces, 2005, 35, 202-214.	1.6	17
64	The epidermal growth factor receptor ligand amphiregulin is a negative regulator of hepatic acute-phase gene expression. Journal of Hepatology, 2009, 51, 1010-1020.	1.8	17
65	Enhancement of Antitumor Vaccination by Targeting Dendritic Cell-Related IL-10. Frontiers in Immunology, 2018, 9, 1923.	2.2	17
66	Cold-Inducible RNA Binding Protein as a Vaccination Platform to Enhance Immunotherapeutic Responses against Hepatocellular Carcinoma. Cancers, 2020, 12, 3397.	1.7	17
67	Synthesis and anti-HIV-1 activities of new pyrimido[5,4-b]indoles. Il Farmaco, 1999, 54, 255-264.	0.9	16
68	The combined actions of NK and T lymphocytes are necessary to reject an EGFP+ mesenchymal tumor through mechanisms dependent on NKG2D and IFNÎ³. International Journal of Cancer, 2007, 121, 1282-1295.	2.3	16
69	Neoantigens as potential vaccines in hepatocellular carcinoma. , 2022, 10, e003978.		16
70	Overcoming class II-linked non-responsiveness to hepatitis B vaccine. Vaccine, 1994, 12, 867-871.	1.7	15
71	Epitope Enhancement of a CD4 HIV Epitope toward the Development of the Next Generation HIV Vaccine. Journal of Immunology, 2006, 176, 3753-3759.	0.4	15
72	A Fusion Protein between Streptavidin and the Endogenous TLR4 Ligand EDA Targets Biotinylated Antigens to Dendritic Cells and Induces T Cell ResponsesIn Vivo. BioMed Research International, 2013, 2013, 1-9.	0.9	15

#	Article	IF	Citations
73	Clinical testing of a dendritic cell targeted therapeutic vaccine in patients with chronic hepatitis C virus infection. Molecular Therapy - Methods and Clinical Development, 2015, 2, 15006.	1.8	15
74	The Toll like receptor 4 ligand cold-inducible RNA-binding protein as vaccination platform against cancer. OncoImmunology, 2018, 7, e1409321.	2.1	15
75	Therapeutic Effect of Irreversible Electroporation in Combination with Poly-ICLC Adjuvant in Preclinical Models of Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology, 2019, 30, 1098-1105.	0.2	15
76	Identification and Characterization of a T-Helper Peptide from Carcinoembryonic Antigen. Clinical Cancer Research, 2004, 10, 2860-2867.	3.2	14
77	Immunomodulatory Properties of Carvone Inhalation and Its Effects on Contextual Fear Memory in Mice. Frontiers in Immunology, 2018, 9, 68.	2.2	14
78	Genetic Modification of CD8+ T Cells to Express EGFR: Potential Application for Adoptive T Cell Therapies. Frontiers in Immunology, 2019, 10, 2990.	2.2	14
79	The mutational load and a T-cell inflamed tumour phenotype identify ovarian cancer patients rendering tumour-reactive T cells from PD-1+ tumour-infiltrating lymphocytes. British Journal of Cancer, 2021, 124, 1138-1149.	2.9	14
80	Therapeutic Vaccines against Hepatocellular Carcinoma in the Immune Checkpoint Inhibitor Era: Time for Neoantigens?. International Journal of Molecular Sciences, 2022, 23, 2022.	1.8	13
81	Induction of potent and long-lasting CD4 and CD8 T-cell responses against hepatitis C virus by immunization with viral antigens plus poly(I:C) and anti-CD40. Antiviral Research, 2007, 74, 25-35.	1.9	12
82	Induction of Multiepitopic and Longâ€Lasting Immune Responses Against Tumour Antigens by Immunization with Peptides, DNA and Recombinant Adenoviruses Expressing Minigenes. Scandinavian Journal of Immunology, 2009, 69, 80-89.	1.3	12
83	In vivo cytotoxic T-lymphocyte induction may take place via CD8+ T helper lymphocytes. Research in Immunology, 1995, 146, 35-44.	0.9	11
84	Identification of HLA-B27-restricted cytotoxic T lymphocyte epitope from carcinoembryonic antigen. International Journal of Cancer, 2002, 97, 58-63.	2.3	11
85	Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses. Emerging Microbes and Infections, 2021, 10, 1931-1946.	3.0	11
86	Cells as vehicles for therapeutic genes to treat liver diseases. Gene Therapy, 2008, 15, 765-771.	2.3	10
87	Characterization of the CD40L/Oncostatin M/Oncostatin M receptor axis as an antiviral and immunostimulatory system disrupted in chronic HCV infection. Journal of Hepatology, 2014, 60, 482-489.	1.8	9
88	Monocyteâ€derived dendritic cells from HCVâ€infected patients transduced with an adenovirus expressing NS3 are functional when stimulated with the TLR3 ligand poly(I:C). Journal of Viral Hepatitis, 2008, 15, 782-789.	1.0	8
89	Tumor therapy in mice by using a tumor antigen linked to modulin peptides from Staphylococcus epidermidis. Vaccine, 2010, 28, 7146-7154.	1.7	8
90	Bivalent therapeutic vaccine against HPV16/18 genotypes consisting of a fusion protein between the extra domain A from human fibronectin and HPV16/18 E7 viral antigens. , 2020, 8, e000704.		8

#	Article	IF	Citations
91	Abstract 4387: Antiviral and antitumoral effects of the anti-CTLA4 agent tremelimumab in patients with hepatocellular carcinoma (HCC) and chronic hepatitis C virus (HCV) infection: Results from a phase II clinical trial. Cancer Research, 2012, 72, 4387-4387.	0.4	8
92	Short Communication: B Cell Epitopes of HIV Type 1 p24 Capsid Protein: A Reassessment. AIDS Research and Human Retroviruses, 1996, 12, 519-525.	0.5	7
93	Inhibition of adjuvant-induced TAM receptors potentiates cancer vaccine immunogenicity and therapeutic efficacy. Cancer Letters, 2021, 499, 279-289.	3.2	7
94	TCR-induced FOXP3 expression by CD8+ T cells impairs their anti-tumor activity. Cancer Letters, 2022, 528, 45-58.	3.2	7
95	Identification of neoantigen-reactive T cells in hepatocellular carcinoma: implication in adoptive T cell therapy. Journal of Hepatology, 2020, 73, S39-S40.	1.8	6
96	Getting insights into hepatocellular carcinoma tumour heterogeneity by multiomics dissection. Gut, 2019, 68, 1913-1914.	6.1	5
97	Metformin keeps CD8+ T cells active and moving in NASH-HCC immunotherapy. Journal of Hepatology, 2022, 77, 593-595.	1.8	5
98	Identification of CD4+ and CD8+ T cell epitopes of woodchuck hepatitis virus core and surface antigens in BALB/c mice. Vaccine, 2010, 28, 5323-5331.	1.7	4
99	Helper cell-independent antitumor activity of potent CD8+T cell epitope peptide vaccines is dependent upon CD40L. OncoImmunology, 2013, 2, e27009.	2.1	3
100	Gene expression analysis during acute hepatitis C virus infection associates dendritic cell activation with viral clearance. Journal of Medical Virology, 2016, 88, 843-851.	2.5	3
101	When Cancer Vaccines Go Viral. Clinical Cancer Research, 2019, 25, 4871-4873.	3.2	3
102	Fine Analysis of Immunoreactivity of V3 Peptides: Antibodies Specific for V3 Domain of Laboratory HIV Type 1 Strains Recognize Multiple V3 Sequences Synthesized from Field HIV Type 1 Isolates. AIDS Research and Human Retroviruses, 1996, 12, 1671-1679.	0.5	2
103	Engineering Th determinants for efficient priming of humoral and cytotoxic T cell responses. International Immunology, 2003, 15, 691-699.	1.8	2
104	MAGE antigens: therapeutic targets in hepatocellular carcinoma?. Journal of Hepatology, 2004, 40, 155-158.	1.8	2
105	Engineered promiscuous T helper peptides for the induction of immune responses. Molecular Immunology, 2007, 44, 2205-2212.	1.0	2
106	387 Protection against infection with an HCV-recombinant vaccinia virus by vaccination with an adenoviral vector enconding hepatitis C virus (HCV) NS4A protein. Journal of Hepatology, 2004, 40, 115-116.	1.8	1
107	Abstract 1059: Enhanced anti-tumor efficacy of a checkpoint inhibitor in combination with the HDAC inhibitor belinostat in a murine hepato-cellular carcinoma preclinical model. Cancer Research, 2017, 77, 1059-1059.	0.4	1
108	Further Insights on the Inhibition of HIV Type 1 Infectionin Vitroby CD4-Modified Synthetic Peptides Containing Phenylalanine. AIDS Research and Human Retroviruses, 1996, 12, 1023-1030.	0.5	0

#	Article	IF	Citations
109	Semblanza Francisco BorrÃ¡s. Inmunologia (Barcelona, Spain: 1987), 2011, 30, 75-76.	0.1	0
110	Dendritic cells: Nearly 40 years laterâ€¦. Inmunologia (Barcelona, Spain: 1987), 2012, 31, 49-57.	0.1	0